Liver Cancer最新文献

{"title":"Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma.","authors":"Yi-Min Zhang, Xin-Tong Wu, Jun-Zhe Yi, Jie Xu, Yu-Nan Zhang, Ning Lyu, Ming Zhao","doi":"10.1159/000545891","DOIUrl":"https://doi.org/10.1159/000545891","url":null,"abstract":"<p><strong>Introduction: </strong>A previous phase 3 FOHAIC-1 study demonstrated that hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen displayed favorable outcomes in advanced hepatocellular carcinoma (HCC) patients, including those with high-risk features (main portal tumor invasion and >50% liver infiltration). This study aimed to compare the treatment efficacy of HAIC-FOLFOX versus atezolizumab-bevacizumab in HCC patients.</p><p><strong>Methods: </strong>Individual patient data from the Chinese FOHAIC-1 study and aggregate data from the global IMbrave150 study were used to conduct an anchored matching-adjusted indirect comparison. Hazard ratios (HR) and restricted mean survival times (RMST) were calculated to assess survival differences. Landmark analysis was performed to evaluate time-sensitive treatment effects, and simulated treatment comparison (STC) was conducted as a sensitivity analysis. Rates of treatment-related adverse events (TRAEs) and TRAE-related discontinuations were also compared.</p><p><strong>Results: </strong>After matching baseline characteristics, HAIC showed a numerical OS benefit (HR 0.57, 95% CI, 0.30-1.08) and similar PFS benefit (HR 0.79, 95% CI, 0.43-1.47) compared to atezolizumab-bevacizumab in the overall population. In high-risk patients, HAIC demonstrated significantly improved OS (HR 0.30, 95% CI, 0.12-0.72) and 2.89-month longer RMST compared to atezolizumab-bevacizumab (95% CI, 0.15-5.64 months). Additionally, HAIC showed superior PFS (HR 0.25, 95% CI, 0.10-0.64) and 2.88-month longer RMST over atezolizumab-bevacizumab (95% CI, 0.90-4.86). Landmark analysis in the high-risk group revealed that HAIC was associated with significant improvements in both OS (HR 0.32, 95% CI, 0.13-0.79) and PFS (HR 0.24, 95% CI, 0.09-0.63) during the 0-12 months following treatment initiation. Sensitivity analysis using the anchored STC analysis yielded consistent results. HAIC was associated with lower rates of grade 3-4 TRAEs and TRAE-related discontinuation in both the overall population and the high-risk group.</p><p><strong>Conclusion: </strong>HAIC treatment provided superior survival benefits and a favorable safety profile compared to atezolizumab-bevacizumab in high-risk HCC patients.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-18"},"PeriodicalIF":11.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Circulating mRNA Variants in Hepatocellular Carcinoma Patients Using Targeted RNAseq.","authors":"Daniel Zezulinski, Maarouf A Hoteit, David E Kaplan, Angela Simeone, Tingting Zhan, Cataldo Doria, Fowsiyo Y Ahmed, Lewis R Roberts, Timothy M Block, Aejaz Sayeed","doi":"10.1159/000545366","DOIUrl":"https://doi.org/10.1159/000545366","url":null,"abstract":"<p><strong>Introduction: </strong>Mutations in circulating nucleic acids can be used as biomarkers for the early detection and management of hepatocellular carcinoma (HCC). However, while circulating tumor DNA and microRNA have been extensively explored, circulating tumor mRNA and circulating mRNA mutants (ctmutRNA), which may provide advantages over other analytes, remain less well described. We previously reported the identification of 288 HCC selective ctmutRNA variants, called \"candidates,\" from a small cohort of HCC patients using total RNAseq. The objective of the current study was to use targeted RNAseq to validate the specificity and sensitivity of these HCC selective variants in an independent cohort of patients with liver cirrhosis (LC).</p><p><strong>Methods: </strong>Several methods to isolate small extracellular vesicles and amplify mRNA from the circulation were compared. RNA was isolated, and the primers and probes selective for the 288 regions of interest were used with RNA from HCC (<i>N</i> = 50) and LC and no HCC (<i>N</i> = 35) patients. HCC tumor tissues (<i>N</i> = 11), a normal liver tissue and 3 cell lines were also studied. cDNA synthesis was followed by library construction using QIAseq RNA Fusion XP panel. QC analysis was carried out with an Agilent Bioanalyzer before sequencing on a NextSeq 550 instrument. A GATK HaplotypeCaller was used for variant calling and annotation carried out using snpEff.</p><p><strong>Results: </strong>Among the test panel of 288 ctmutRNA candidates in the original cohort, 75 were detected in the new cohort of plasma samples. Moreover, 388 other variants in proximity to the original lesions were also found in multiple HCC but not LC plasma samples. A subset of 36 HCC selective variants was able to identify all HCC patients. The most common tumor specific variants were Indels and SNPs. Novel mRNA fusion variants, corresponding to SENP7, HYI, SAR1A, RASA2, TUBA transcripts, etc., were identified in HCC and LC patients.</p><p><strong>Conclusion: </strong>Circulating RNA could be a robust analyte for noninvasive early detection of HCC and circulating RNA panels could be powerful tools in the entire spectrum of clinical management.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-32"},"PeriodicalIF":11.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.","authors":"Zhaolong Pan, Dongming Liu, Junbo Cao, Linlin Fu, Xihao Zhang, Xiaodong Zhu, Yangxun Pan, Jianwei Liu, Chuangye Han, Renan Jin, Shunli Shen, Xiaoyun Zhang, Hongzhi Liu, Xiaobo Yang, Kuan Hu, Xiaoyi Shi, Dongxu Wang, Yang Zhao, Jianhong Zhong, Bangde Xiang, Shanzhi Gu, Tao Li, Shuijun Zhang, Ledu Zhou, Haitao Zhao, Yongyi Zeng, Tianfu Wen, Ming Kuang, Xiao Liang, Tao Peng, Kui Wang, Li Xu, Huikai Li, Tianqiang Song, Huichuan Sun, Wei Zhang","doi":"10.1159/000545545","DOIUrl":"10.1159/000545545","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The conversion therapy for advanced hepatocellular carcinoma (HCC) shows promise with a triple therapy approach that combines interventional therapy, immune checkpoint inhibitors, and molecular targeted therapy (primarily small-molecule TKIs and the large-molecule bevacizumab). This combination has achieved the highest objective response rates (ORR) along with acceptable safety profiles. The aim of this study was to compare the clinical efficacy of lenvatinib versus bevacizumab, when combined with immune checkpoint inhibitors and interventional triple therapy, as first-line treatments for Chinese patients with unresectable HCC (uHCC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Method: &lt;/strong&gt;This retrospective multicenter study involved 371 consecutive patients from 21 centers in China, observed between April 2017 and December 2023. The study focused on patients with uHCC at Chinese liver cancer stages IIb to IIIb (Barcelona Clinic Liver Cancer stage B or C) who received lenvatinib or bevacizumab combined with anti-PD-1/L1 and interventional therapy (including TACE and/or HAIC) as first-line treatment. Of the 371 patients, 258 received lenvatinib-based triple therapy, while 113 received bevacizumab-based triple therapy. The primary endpoints were overall survival (OS) and progression-free survival (PFS). To balance baseline clinical characteristics, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were applied. Subgroup analysis was also performed based on different clinicopathological characteristics of the enrolled uHCC patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The median OS in the lenvatinib group was significantly longer than in the bevacizumab group, both before (36.0 vs. 27.9 months; hazard ratio [HR]: 0.536; 95% confidence interval [CI]: 0.344-0.835; &lt;i&gt;p&lt;/i&gt; = 0.0016) and after PSM (HR: 0.524; 95% CI: 0.305-0.900; &lt;i&gt;p&lt;/i&gt; = 0.01), as well as after IPTW (HR: 0.549; 95% CI: 0.331-0.908; &lt;i&gt;p&lt;/i&gt; = 0.01). Before adjustment, PFS in the lenvatinib group was also significantly longer than in the bevacizumab group (20.0 vs. 12.1 months; HR: 0.649; 95% CI: 0.457-0.922; &lt;i&gt;p&lt;/i&gt; = 0.0078). However, after PSM (HR: 0.808; 95% CI: 0.535-1.222; &lt;i&gt;p&lt;/i&gt; = 0.33) and IPTW, there was no significant difference in PFS between the two groups. Multivariate analysis showed that lenvatinib-based triple therapy was independently associated with improved OS compared to bevacizumab-based triple therapy. Subgroup analysis indicated that patients with age ≤65 years, no history of hepatitis B virus infection, Barcelona Clinic Liver Cancer stage C (BCLC-C), ALT levels ≤40 U/L, platelets ≥100 × 10&lt;sup&gt;9&lt;/sup&gt;/L, or log 10 AFP ≥1.40 benefited more from lenvatinib-based triple therapy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Lenvatinib-based triple therapy tends to prolong OS compared to bevacizumab, although the PFS was similar between the two groups. Patients aged ≤65 years, without a history of hepatitis B virus infection, with B","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-19"},"PeriodicalIF":11.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease.","authors":"Jessica Spiers, Wenhao Li, Aloysious D Aravinthan, Ayman Bannaga, Katharine Caddick, Emma L Culver, Rosemary E Faulkes, Victoria Gordon, Yaqza Hussain, Hamish Miller, Jenny Merry, Muhammad Saad, Abhishek Sheth, Tahir Shah, Shishir Shetty, Ankur Srivastava, Mohsan Subhani, Muhammad Nauman Tahir, Nwe Ni Than, Esther Unitt, William Alazawi","doi":"10.1159/000542805","DOIUrl":"https://doi.org/10.1159/000542805","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Current international guidelines recommend 6-monthly ultrasound surveillance in all patients with cirrhosis and those with hepatitis B virus-related risk factors to detect early-stage HCC. However, it is unknown whether the benefits of surveillance are comparable across patient groups and underlying disease-related factors. We aimed to evaluate patient- and disease-related factors associated with HCC stage at diagnosis and survival in an ethnically diverse UK population.</p><p><strong>Methods: </strong>This was a multicentre retrospective observational study including patients with newly diagnosed HCC between 2007 and 2020 from six UK centres. Cox proportional-hazards regression and multivariate logistic regression models were used.</p><p><strong>Results: </strong>Overall, 1,780 HCC patients comprising 20.9% with ArLD, 29.7% with NAFLD, and 31.0% with viral hepatitis were analysed. Surveillance was associated with improved survival in patients with viral hepatitis but not in patients with ArLD and NAFLD. Surveillance was also associated with early-stage disease (BCLC stage 0 or A) at presentation in viral hepatitis but not in patients with ArLD. Females with ArLD were 2.5-fold more likely to present with early-stage HCC than males. Patients with NAFLD were more likely to develop HCC in the absence of cirrhosis. Type 2 diabetes was not associated with mortality, but metformin use did show survival benefit. Patients of white ethnicity had improved survival and were less likely to present with late-stage HCC compared to other ethnicities.</p><p><strong>Conclusions: </strong>HCC surveillance as currently delivered was less effective for detecting early-stage HCC in patients with non-viral and non-cirrhotic liver disease. Gender and ethnicity influences stage at presentation and outcomes. HCC surveillance strategies are needed to refine risk stratification particularly in patients with NAFLD or without cirrhosis.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-14"},"PeriodicalIF":11.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens.","authors":"Masatoshi Kudo","doi":"10.1159/000545163","DOIUrl":"https://doi.org/10.1159/000545163","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"119-126"},"PeriodicalIF":11.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation.","authors":"Wen-Jing Zheng, Yang Xu, Hui Tan, Shu-Guang Chen, Peng-Xiang Wang, Hai-Xiang Sun, Rui-Zhe Li, Hai-Ying Zeng, Yu-Chen Zhong, Jian-Wen Cheng, Jia Fan, Jian Zhou, Hongcheng Shi, Xin-Rong Yang","doi":"10.1159/000544966","DOIUrl":"https://doi.org/10.1159/000544966","url":null,"abstract":"<p><strong>Introduction: </strong>In addition to radical resection, liver transplantation (LTx) is an effective treatment for hepatocellular carcinoma (HCC). However, tumor recurrence limits the efficacy of LTx in some patients. This study investigated the role of ¹⁸F-fludeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting the prognosis of patients with HCC after LTx.</p><p><strong>Methods: </strong>A total of 278 consecutive patients with HCC who underwent pre-LTx PET/CT were divided into derivation (<i>n</i> = 178) and temporal validation (<i>n</i> = 100) cohorts and evaluated for PET/CT values, immunohistochemical (IHC) findings, and DNA sequencing of tumor tissues.</p><p><strong>Results: </strong>Patients with post-LTx recurrence exhibited significantly higher tumor maximum standardized uptake values (SUVmax) in pre-LTx PET/CT scans. Receiver operating characteristic curve analyses identified the tumor SUVmax to liver SUVmax ratio (T_SUVmax/L_SUVmax) as the strongest predictor of post-LTx recurrence, with an optimal cutoff value of 1.43. Kaplan-Meier analyses demonstrated that a T_SUVmax/L_SUVmax >1.43 was associated with a shorter time to recurrence (TTR) and overall survival (OS) in both cohorts (<i>p</i> < 0.001 for both). Multivariate Cox regression analyses confirmed that T_SUVmax/L_SUVmax >1.43 was an independent risk factor for tumor recurrence in both cohorts. IHC revealed that T_SUVmax/L_SUVmax >1.43 correlated with higher Ki-67 and CK19 expression. DNA sequencing indicated that tumors with T_SUVmax/L_SUVmax >1.43 had more mutations and a higher TMB. Furthermore, T_SUVmax/L_SUVmax >1.43 was significantly associated with mutations in <i>TP53</i>, <i>EPPK1</i>, <i>MDM4</i>, <i>SLAMF7</i>, <i>SDHC</i>, <i>B4GALT3</i>, <i>RXRG</i>, and FCGR family genes, as well as TP53 and PI3K signaling-related alterations.</p><p><strong>Conclusions: </strong>The preoperative T_SUVmax/L_SUVmax is a potential predictor of tumor recurrence in patients with HCC following LTx. Its use improves candidate selection and post-LTx management.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-21"},"PeriodicalIF":11.6,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.","authors":"Masatoshi Kudo, Tatsuya Yamashita, Richard S Finn, Peter R Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take, Kyoko Yamada, Yuki Nakagawa, Hayato Takahashi, Masafumi Ikeda","doi":"10.1159/000544981","DOIUrl":"https://doi.org/10.1159/000544981","url":null,"abstract":"<p><strong>Introduction: </strong>IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR).</p><p><strong>Methods: </strong>IMbrave150 was a phase III randomized study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable HCC. DpR was defined as maximum tumor shrinkage from baseline based on the sum of longest diameters per independent review facility (IRF)-assessed RECIST 1.1. DoR was defined as time from first complete/partial response by IRF-assessed RECIST 1.1 until progression or death. Associations between OS and DpR or DoR were evaluated by scatterplot in both arms; OS and PFS were evaluated by DpR in atezolizumab plus bevacizumab-treated patients. To minimize immortal time bias, the DpR analysis included patients who survived ≥6 months.</p><p><strong>Results: </strong>Of 312 and 140 patients with baseline measurable disease in the atezolizumab plus bevacizumab and sorafenib arms, respectively, 264 and 99 surviving ≥6 months were included in the DpR analysis, and 97 and 18 in the DoR analysis. Tumor shrinkage occurred in 230/312 (74%) patients in the atezolizumab plus bevacizumab arm and 76/140 (54%) in the sorafenib arm; their mean (SD) DpR was -42.5% (32.4%) and -25.0% (21.9%), respectively. Atezolizumab plus bevacizumab-treated ≥6-month survivors with DpR <0% had improved OS versus those with DpR ≥0% (HR: 0.29; 95% CI: 0.19-0.44). Those with deeper responses (DpR -100% to -60%) had longer OS than those with DpR ≥20% (unstratified HR: 0.08; 95% CI: 0.03-0.21). In scatterplots, DpR and DoR were generally associated with OS in both arms; interpretation was limited by censored patients.</p><p><strong>Conclusions: </strong>DpR and DoR to atezolizumab plus bevacizumab and sorafenib were associated with OS in patients with unresectable HCC. More longer, deeper responses occurred with atezolizumab plus bevacizumab.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-16"},"PeriodicalIF":11.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.","authors":"Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, Hyunchul Rhim, Ping Liang, Uei Pua, Masatoshi Tanaka, Peihong Wu","doi":"10.1159/000544976","DOIUrl":"https://doi.org/10.1159/000544976","url":null,"abstract":"<p><p>Globally, the incidence and associated mortality of primary liver cancer have been steadily increasing. Currently, 80% of cases are found in Asia. Curative resection is applicable in only 20% of patients; therefore, various nonsurgical treatment modalities have been developed. Image-guided percutaneous liver tumor ablation is regarded as the best option for treating early-stage hepatocellular carcinoma (HCC). However, skills and knowledge in ablation can vary among operators. Furthermore, Asia has the highest number of ablation procedures for HCC and the largest number of doctors performing ablation worldwide. Thus, the Asian Conference on Tumor Ablation has developed guidelines for HCC. These guidelines will discuss indications, pre-ablative diagnosis and planning, techniques, peri-ablative management, evaluation of therapeutic effectiveness, complications, post-ablative follow-up, prevention of recurrence, and treatment of recurrence for HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-27"},"PeriodicalIF":11.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma.","authors":"Masatoshi Kudo","doi":"10.1159/000543245","DOIUrl":"10.1159/000543245","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 1","pages":"1-7"},"PeriodicalIF":11.6,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.","authors":"Masatoshi Kudo","doi":"10.1159/000542221","DOIUrl":"10.1159/000542221","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"13 6","pages":"573-578"},"PeriodicalIF":11.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142837140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}